who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes James Hury of TRISH, Serafina Lalany of HX, and Andrew Ramirez of Village Insights. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space health to virtual collaboration — recently making headlines in Houston innovation.

James Hury, deputy director and chief innovation officer of TRISH

James Hury joins the Houston Innovators Podcast to discuss the role of the Translational Research Institute for Space Health. Photo courtesy of TRISH

Only about 500 humans have made it to space, and that number is getting bigger thanks to commercial space travel.

"If you look at all the people who have gone into space, they've mostly been employees of nations — astronauts from different governments," says James Hury of the Translational Research Institute for Space Health on this week's episode of the Houston Innovators Podcast. "We're going to start to get people from all different ages and backgrounds."

Hury is the deputy director and chief innovation officer for Houston-based TRISH, and he's focused on identifying space tech and research ahead of the market that has the potential to impact human health in space. From devices that allow astronauts to perform remote health care on themselves to addressing behavioral health challenges, TRISH is supporting the future of space health. Click here to read more and stream the podcast.

Serafina Lalany, executive director of Houston Exponential

Serafina Lalany, vice president of operations at Houston Exponential

HX has its new permanent leader. Photo courtesy of Serafina Lalany

Houston's nonprofit focused on accelerating the growth of the local innovation ecosystem has named its new leader.

Serafina Lalany has been named Houston Exponential's executive director. She has been serving in the position as interim since July when Harvin Moore stepped down. Prior to that, she served as vice president of operations and chief of staff at HX.

"I'm proud to be leading an organization that is focused on elevating Houston's startup strengths on a global scale while helping to make the world of entrepreneurship more accessible, less opaque, and easier to navigate for founders," Lalany says in a news release. "My team and I will be building upon the great deal of momentum that has already been established in this effort, and I look forward to collaborating closely with members of our community and convening board in this next chapter of HX." Click here to read more.

Andrew Ramirez, CEO of Village Insights

Andrew Ramirez originally worked on a similar project 10 years ago. Photo via LinkedIn

Innovation thrives on collisions, but how do innovators connect without face-to-face connection? Andrew Ramirez and Mike Francis set out to design a virtual village to promote collisions and innovation, and their platform is arriving at an apt time.

"The world has changed," Ramirez says. "I feel like people are trying to find the right balance of the physical but also the productivity gain from being able to do things digitally."

Ramirez leads Village Insights as CEO and the new platform is expected to formally launch it's Open World platform next month. Click here to read more.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News